Follow-up work, however, has shed a positive light on the impact of IL-18-producing CAR T cells to augment tumor immunity, which inspired a clinical trial testing the impact of IL-18 secretion by anti-CD19 CAR T cells in patients [127]. Here, CD19 is linked to neoplasm.